Portal de investigación
Iron deficiency and safety of ferric carboxymaltose in patients with acute heart failure. AHF-ID study
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Jacob J.
- Miró Ò.
- Ferre C.
- Borraz-Ordás C.
- Llopis-García G.
- Comabella R.
- Fernández-Cañadas J.M.
- Mercado A.
- Roset A.
- Richard-Espiga F.
- Valero-Domènech A.
- Martínez-Gimeno J.L.
- Martín-Sánchez F.J.
- Llorens P.
- Álvarez-Pérez J.M.
- López-Díez P.
- Herrero-Puente P.
- Comín-Colet J.
Grupos
Abstract
Introduction: The presence of iron deficiency (ID) in patients with acute heart failure (AHF) is high. There are few studies on the characteristics of these patients and the safety of ferric carboxymaltose administration (FCM). Objective: Study the differences among patients with AHF based on the presence and type of ID as well as the safety of FCM administration in these patients. Method: The AHF-ID study is a multicentre, analytical, prospective follow-up cohort including patients admitted to six Spanish hospitals for AHF. ID was defined as serum ferritin <100 µg/L (group A) or ferritin 100-299 µg/L with a TSAT <20% (group B). In cases receiving FCM the appearance of adverse events was analysed. Adjusted Cox regression was used to determine the association with 30-days reattendance for AHF after discharge. Results: A total of 221 patients were recruited; 191 (86.4%) presented ID, 121 (63.4%) group A and 70 (36.6%) group B. There were scarce differences between the groups analysed. No differences were found in 30-days reattendance for AHF. FCM was administered to 158 (71.5%) patients, with 8 (5.1%) presenting adverse events, the most frequent being digestive alterations. Treatment was not discontinued in any case. Conclusions: There are scarce differences between the presence and the type of ID in patients with AHF. The administration of FCM in patients with ID and AHF is safe. © 2020 John Wiley & Sons Ltd
Datos de la publicación
- ISSN/ISSNe:
- 1368-5031, 1742-1241
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1111/ijcp.13584
- PubMed:
- 32533907
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,756 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE WILEY
Documentos
- No hay documentos
Filiaciones
Keywords
- Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Heart Failure; Humans; Male; Maltose; Middle Aged; Prospective Studies; Treatment Outcome; acetylsalicylic acid; amiodarone; angiotensin receptor antagonist; anticoagulant agent; beta adrenergic receptor blocking agent; calcium antagonist; dipeptidyl carboxypeptidase inhibitor; ferric carboxymaltose; ferritin; loop diuretic agent; mineralocorticoid antagonist; thiazide diuretic agent; ferric carboxymaltose; ferric ion; ferritin; maltose; acute heart failure; adult; aged; Article; cardiac patient; cohort analysis; controlled study; disease classification; drug safety; female; ferritin blood level; follow up; gastrointestinal disease; heart failure; hospital; hospital discharge; human; iron deficiency; major clinical study; male; multicenter study; priority journal; proportional hazards model; prospective study; Spain; thromboembolism; blood; complication; iron deficiency anemia; middle aged; treatment outcome